M 1231
Alternative Names: Bispecific anti-MUC1xEGFR antibody-drug conjugate; M-1231; MUC1/EGFR bi-specific ADCLatest Information Update: 21 Jul 2023
At a glance
- Originator Sutro Biopharma
- Developer EMD Serono; Merck KGaA
- Class Antineoplastics; Bispecific antibodies; Drug conjugates; Immunoconjugates
- Mechanism of Action Tubulin inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Non-small cell lung cancer; Oesophageal cancer; Solid tumours; Squamous cell cancer
Most Recent Events
- 26 Jun 2023 Discontinued - Phase-I for Non-small cell lung cancer (Late-stage disease, Refractory metastatic disease) in Canada (Parenteral) (Sutro Biopharma pipeline, June 2023)
- 26 Jun 2023 Discontinued - Phase-I for Oesophageal cancer (Late-stage disease, Refractory metastatic disease) in Canada (Parenteral) (Sutro Biopharma pipeline, June 2023)
- 26 Jun 2023 Discontinued - Phase-I for Solid tumours (Late-stage disease, Refractory metastatic disease) in Canada (Parenteral) (Sutro Biopharma pipeline, June 2023)